Navigation Links
Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
Date:7/28/2008

SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) announced the appointment of Paul A. Foster, M.D. as Chief Medical Officer to lead the Company's late-stage clinical development activities at Cardium's Tissue Repair Company for the MATRIX Phase 2b clinical study that is evaluating its Excellarate product candidate for the treatment of diabetic ulcers, and the AWARE Phase 3 clinical study that is evaluating its Generx product candidate as a potential treatment for recurrent myocardial ischemia. Dr. Foster, who is currently Cardium's Vice President and Medical Officer, will assume study oversight responsibilities for both Cardium's and the Tissue Repair Company's clinical programs. Dr. Robert Engler, the Company's Chief Medical Advisor who has been involved in the Generx trials since their inception, will continue to play an active role in those studies, and Dr. Randall Moreadith will continue to focus on evaluating potential new business development and medical device opportunities for the Company.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

"We are very pleased to have Paul head up development of our key product candidates as they move through late-stage clinical trials," stated Christopher J. Reinhard, Chief Executive Officer and Chairman of Cardium Therapeutics. "Paul's leadership and extensive clinical experience will greatly assist us as we advance our Generx candidate now in Phase 3, and Tissue Repair's Excellarate candidate, which is expected to complete its key Phase 2 study this year."

Dr. Foster was previously Chief Medical Officer and Vice President of Clinical Development and
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, Inc. ... announced it has completed the sale to Galderma of ... owned or held by Valeant for $1.4 billion in ... S.A, which recently completed its acquisition of Galderma. ... of our products to a company that is firmly ...
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation (NYSE: ... directors has approved a quarterly dividend of $0.275 (27.5 cents) ... payable on August 1, 2014, to holders of record on ... CVS Caremark is dedicated to helping people on their ... in the United States . Through the ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... LONDON, Sept. 1 The pharmacy automation systems ... spurt. Until recently, most pharmacies have been either ... systems. In response, the adoption rate of automation ... prescription management systems to advanced medication pick-up and ...
... WARSAW, Ind., Aug. 31 Zimmer Holdings, Inc. (NYSE: ... care, announced that it will be participating in the Morgan ... on September 13, 2010 at 8:35 a.m. Eastern Time. ... via Zimmer,s Investor Relations website at http://investor.zimmer.com .  The ...
Cached Medicine Technology:Low Installation Rates in Retail Pharmacies Across Europe Increase the Growth Potential of the Pharmacy Automation Systems Market, Finds Frost & Sullivan 2Low Installation Rates in Retail Pharmacies Across Europe Increase the Growth Potential of the Pharmacy Automation Systems Market, Finds Frost & Sullivan 3Zimmer Holdings to Present at Morgan Stanley Global Healthcare Unplugged Conference 2Zimmer Holdings to Present at Morgan Stanley Global Healthcare Unplugged Conference 3
(Date:7/11/2014)... Europe Well Intervention Market report defines and segments the well ... The well intervention services market in Europe is estimated to ... by 2018, at a CAGR of 7% from 2013 to ... Intervention Market report, to get an idea of the in-depth ... in the Europe well intervention market, and is supported by ...
(Date:7/11/2014)... News) -- In people with sex addiction, pornography affects ... seen in drug addicts as they consume drugs, a ... brain activity between patients who have compulsive sexual behavior ... addicts," study author Dr. Valerie Voon, of the University ... release. Voon,s research involved 19 men with sex ...
(Date:7/11/2014)... The report “Probiotics Market by Products (Functional ... (Regular, Therapeutic, Preventive Health Care) & Ingredients (Lactobacilli, ... 2019 ” defines and segments the global probiotics ... market value of probiotic products and ingredients. The ... for the global market with an analysis of ...
(Date:7/11/2014)... 2014 Biostimulants are widely applied in ... and ornamentals. These also help turf and ornamentals in ... roots. Turf, ornamentals, and flowers appear healthy and strong ... has increased from the last few years. The most ... is Europe, with around 40% share in 2013, and ...
(Date:7/11/2014)... 2014) Obese and overweight firefighters are not ... providers, according to new research from The University ... , National guidelines state that health care professionals ... maintaining a healthy weight. Firefighters have high rates ... cause of line-of-duty deaths in firefighters. This study ...
Breaking Medicine News(10 mins):Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
... innovative approach to treating neonatal feeding problems at Nationwide ... feed orally to be discharged earlier and without feeding ... According to American Academy of Pediatrics guidelines, in ... hospital, they must establish safe oral feeding methods. The ...
... This press release is available in German . ... the biggest risk factors for the development of gastric cancer, the ... biologists from the University of Zurich have now identified a mechanism ... gastric mucosa and sets them up for malignant transformation. Gastric ...
... -- Doctors have been prescribing codeine for postpartum pain management ... to breastfeed while taking the opioid. But the death ... many health care providers questioning the safety of the drug ... risks, some doctors have begun the practice of prescribing oxycodone ...
... HealthDay Reporter , MONDAY, Sept. 5 (HealthDay News) -- Living ... as much as 80 percent, researchers from the U.S. National ... diet, exercise, smoking and drinking have an impact on whether ... each individual factor affects the risk had been unclear. ...
... 6 (HealthDay News) -- There,s no link between menopause ... a study that challenges a long-held medical belief that ... menopause. Aging alone, not the hormonal impact of ... women, according to the Johns Hopkins researchers. The ...
... Sept. 6 (HealthDay News) -- Some children, especially those ... the hospital, a new study finds. Acetaminophen, albuterol ... hospitalized children, the researchers said. They also found an ... of drugs given to children. On the first ...
Cached Medicine News:Health News:Neonatal and infant feeding disorders program saves infants from lifetime of feeding tubes 2Health News:Stomach bacterium damages human DNA 2Health News:Mother's postpartum oxycodone use: No safer for breastfed infants than codeine 2Health News:Healthy Living Can Cut Chances of Developing Diabetes 2Health News:Aging, Not Menopause, Raises Women's Heart Risks, Study Finds 2Health News:Hospitalized Kids May Receive Up to 35 Meds a Week 2
... Beta 200 ophthalmoscope, ... glare-free direct ophthalmoscope. Heine's ... patent #4,963,014) along with ... construction, make the Beta ...
... optics. The separation of illumination and observation ... system avoids corneal and iris reflex (Gullstrand-principle). ... the whole of the illuminated section of ... Conventional ophthalmoscopes often let you see only ...
... Beta 200S is the first ... combination of patented aspherical optics ... range of corrective lenses from ... single diopter steps. A perfectly-focused ...
With the unique automatic focus system, Autofoc 2 remains the instrument of choice for direct ophthalmoscopy. Includes XHL halogen bulb....
Medicine Products: